Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …

Background Alzheimer's disease and its complications are the leading cause of death in
adults with Down syndrome. Studies have assessed Alzheimer's disease in individuals with …

Objectives: To estimate a regional progression pattern of amyloid deposition from cross-
sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging of an …

Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Epidemiological and experimental studies suggest that a disease-aggravating
neuroinflammatory process is present at preclinical stages of Alzheimer's disease. Given …

Individuals with Down syndrome (DS) are more likely to experience earlier onset of multiple
facets of physiological aging. This includes brain atrophy, beta amyloid deposition, cognitive …

Importance Alzheimer disease (AD) is the leading cause of death in individuals with Down
syndrome (DS). Previous studies have suggested that theAPOEɛ4 allele plays a role in the …

Down syndrome (DS) is associated with a variety of cognitive impairments, notably memory
impairments. Due to the high prevalence rates of early-onset dementia associated with DS, it …

Improved medical care of individuals with Down syndrome (DS) has led to an increase in life
expectancy to over the age of 60 years. In conjunction, there has been an increase in age …